S/N 10/769,731 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

BOND

Examiner:

UNKNOWN

Serial No.:

10/769,731

Group Art Unit:

1632

Filed:

JANUARY 16, 2004

Docket No.:

11669.136USU1

Confirmation No.:

6901

Customer No.:

23552

Title:

SYNTHETIC ANTIBODY PHAGE LIBRARIES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. §1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

The Deposit Account No. 13-2725 is being charges for consideration of the items listed on the enclosed Form 1449. Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C. P.O. Box 2903

Minneapolis, Minnesota 55402-0903

(612) 332-5300

Date: april 30, 2007

Katherine M. Kowalchyk

Reg. No. 36,848

23552

Date filed: April 30, 2007 Sheet I of 2

FORM 1449* INFORMATION DISCLOSURE STATEMENT	INFORMATION DISCLOSURE STATEMENT	Docket Number: 11669.136USU1	Application Number: 10/759,731	
IN AN APPLICATION (Use several sheets if necessary)		Applicant: BOND		
		Filing Date: 01/16/2004	Group Art Unit: 1632	

	T	·		7	T	1	
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	1	G DATE OPRIATE
	4,816,567	03/28/1989	Cabilly et al.				
	6,037,454	03/14/2000	Jardieu et al.				
	6,627,196 B1	09/30/2003	Baughman et al.				
		FO	REIGN PATENT DOC	UMENTS			
		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
WO 93/06213		4/01/1993	PCT				
WO 93/19172		9/30/1993	РСТ				
·····	нто	ER DOCUMENT	ΓS (Including Author, Ti	tle, Date, Pertinen	t Pages, Etc.)		
	Bond, C. et al., (2005)	"A Structure-Base	d Database of Antibody	Variable Domain	Diversity", <u>J. Mol. E</u>	<u>liol.</u> , 348:699	9-709
			High Efficiency Plasmid		A Escherichia coli S	Strain With E	Beta-
	Crea, R. et al., "Chemical synthesis of genes for human insulin", Proc. Natl. Sci. USA, 75(12):5765-4769 (1978)						
	Davies, B. et al. "Interactions of Protein antigens with Antibodies", Proc. Natl. Sci. USA, 93:7-12(1996)						
		itibody: Structural	re of a Staphylococcus at basis for recognition of				
	Mian, I. et al., "Structure, Function and Properties of Antibody Binding Sites", <u>J. Mol. Biol.</u> , 217:133-151 (1991)						
		al., "Chimeric hun S, 81:6851-6855 (nan antibody molecules:	Mouse antigen-bii	nding domains with	human const	ant region
	Wu. T. et al., "A	An Analysis of the	Sequences of the Variab	le Regions of Ben	ce Iones Proteins an	d Myeloma l	Light

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Date filed: April 30, 2007 Sheet 2 of 2

FORM 1449*	INFORMATION DISCLOSURE STATEMENT	Docket Number: Application Number: 11669.136USU1 10/759,731		
IN AN APPLICATION (Use several sheets if necessary)		Applicant: BOND		
		Filing Date: 01/16/2004	Group Art Unit: 1632	

	Chains and Their Implications for Antibody Complementarity", J. Exp. Med., 132:211-250 (1970)
	Zemlin et al, "Expressed Murine and Human CDR-H3 Intervals of Equal Length Exhibit distinct repertoires that differ in amino acid composition and predicted structures", J. Mol. Biol. 334:733(2003)

23552
PATENT TRADEMARK OFFICE

EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.